GlobeNewswire: Adverum Biotechnologies, Inc. Contains the last 10 of 262 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:10:52ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/18/2848148/0/en/Adverum-Biotechnologies-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Pipeline-Highlights-and-Corporate-Updates.html?f=22&fvtc=4&fvtv=22846Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates2024-03-18T20:05:00Z<![CDATA[- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD -]]>https://www.globenewswire.com/news-release/2024/02/28/2837406/0/en/Adverum-Biotechnologies-to-Participate-in-the-TD-Cowen-44th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=22846Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference2024-02-28T21:05:00Z<![CDATA[REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:10 a.m. ET.]]>https://www.globenewswire.com/news-release/2024/02/12/2827495/0/en/Adverum-Biotechnologies-to-Participate-in-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html?f=22&fvtc=4&fvtv=22846Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference2024-02-12T13:00:00Z<![CDATA[REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th, 2024 at 12:00 p.m. ET.]]>https://www.globenewswire.com/news-release/2024/02/08/2825871/0/en/Adverum-Biotechnologies-Announces-Positive-Preliminary-Efficacy-and-Safety-Data-from-LUNA-Phase-2-Trial-of-Ixo-vec-in-Patients-with-Wet-AMD.html?f=22&fvtc=4&fvtv=22846Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD2024-02-08T12:00:00Z<![CDATA[– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –]]>https://www.globenewswire.com/news-release/2024/02/05/2823441/0/en/Adverum-Biotechnologies-Announces-127-5-Million-Private-Placement-Financing.html?f=22&fvtc=4&fvtv=22846Adverum Biotechnologies Announces $127.5 Million Private Placement Financing2024-02-05T12:45:00Z<![CDATA[- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners and Vivo Capital, as well two large investment management firms.]]>https://www.globenewswire.com/news-release/2024/02/01/2822523/0/en/Adverum-Biotechnologies-will-Host-Webcast-to-Review-LUNA-Phase-2-Preliminary-Efficacy-and-Safety-Results-on-February-8-2024.html?f=22&fvtc=4&fvtv=22846Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 20242024-02-01T22:30:00Z<![CDATA[- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET -]]>https://www.globenewswire.com/news-release/2024/01/29/2818844/0/en/Adverum-Biotechnologies-Appoints-Romuald-Corbau-Ph-D-as-Chief-Scientific-Officer.html?f=22&fvtc=4&fvtv=22846Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer2024-01-29T13:00:00Z<![CDATA[REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer. Dr. Corbau will serve as a member of Adverum’s executive committee.]]>https://www.globenewswire.com/news-release/2023/12/07/2792889/0/en/Adverum-Biotechnologies-to-Present-LUNA-Preliminary-Efficacy-and-Safety-Data-at-the-47th-Annual-Meeting-of-the-Macula-Society.html?f=22&fvtc=4&fvtv=22846Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society2023-12-07T21:05:00Z<![CDATA[REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024.]]>https://www.globenewswire.com/news-release/2023/11/28/2787352/0/en/Adverum-Biotechnologies-to-Participate-in-the-Evercore-ISI-6th-Annual-HealthCONx-Conference.html?f=22&fvtc=4&fvtv=22846Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference2023-11-28T21:05:00Z<![CDATA[REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Wednesday, November 29, 2023 at 3:50 p.m. ET in Miami, Florida.]]>https://www.globenewswire.com/news-release/2023/11/09/2777800/0/en/Adverum-Biotechnologies-Reports-Third-Quarter-2023-Financial-Results-and-Pipeline-Highlights.html?f=22&fvtc=4&fvtv=22846Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights2023-11-09T21:05:00Z<![CDATA[- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC trial -]]>